Predict your next investment

HEALTHCARE | Pharmaceutical Distribution & Wholesale
corepharma.com

See what CB Insights has to offer

Stage

Loan | Acquired

Total Raised

$680K

About CorePharma

CorePharma is a developer, manufacturer and marketer of high-quality, targeted, generic prescription pharmaceuticals across a variety of dosage forms and therapeutic categories.

CorePharma Headquarter Location

215 Wood Ave.

Middlesex, New Jersey, 08846,

United States

732-868-1090

Latest CorePharma News

Mark Cuban Is Going To Help Big Pharma’s Image

Jan 19, 2021

In his terrific book, The Great American Drug Deal , Peter Kolchinsky talks about one of the most common surgical procedures – hip replacements. There are over 400,000 such procedures done in the U.S. annually. In fact, given my age, I now have a handful of friends who have had at least one hip done. Hip replacement surgeries were first carried out in the 1940s and, while the methodology has improved, the procedure is essentially the same today and costs about $40,000 (not including extended nursing and rehabilitation). This surgery cost the U.S. healthcare system about $16 billion in 2019 - a figure that will undoubtedly continue to grow. (Photo by Steven Ferdman/Getty Images) Getty Images Contrast this with the important heart drug, Lipitor. This Pfizer product had peak annual sales of almost $13 billion. Yet, once the patent for Lipitor expired, there was almost a 95% drop in U.S. revenue. Today, atorvastatin, the generic name of Lipitor, is the THIRD most prescribed drug in the U.S. and, depending on the pharmacy you choose, you can buy a thirty-day supply of the 10mg dose for a mere $8. It is believed that statins have contributed to a 50% decline in deaths due to heart attacks and strokes. That’s a pretty good deal for a pill that costs about a quarter a day. This is the basis of Kolchinsky’s Great American Drug Deal. “Doctors and hospitals don’t go generic……Drugs going generic is the cost-containment mechanism we have long had.” But, despite the great value of generic drugs, the system isn’t foolproof. Sometimes it breaks down. Take the case of Daraprim (generic name, pyrimethamine), an old antimalarial drug still used to treat toxoplasmosis, a parasitic infection that can cause life-threatening issues for people with a depressed immune system. GSK sold Daraprim for decades but at $2 a pill, it wasn’t a big money maker and so in 2010 GSK sold the rights to Daraprim to CorePharma. CorePharma promptly raised the price of Daraprim to $13.50 a pill. (CorePharma was later bought by Impax.) Yet, despite this increase, nary a complaint was raised. This was such a minor part of hospital budgets that the increase was simply accepted. Even after this price increase, Daraprim sales were less than $10 million annually. Enter Martin Shkreli whose company, Turing Pharmaceuticals, next bought the rights to Daraprim. Shkreli claimed that, since this was a life-saving drug, Daraprim merited a much higher price – and immediately raised the cost to $750 a pill. The outrage was instantaneous. CorePharma, Impax and Turning had done nothing to justify these increases. There had been no new research done that justified any of these increases. It was simply a case of corporate greed. And, as Turing at the time was the only manufacturer of Daraprim, it had the market to itself. (A generic version was finally approved by the FDA in early 2020.) The promise of a low cost generic was no longer being realized for Daraprim. While it was a generic company that created this scandal, the blowback to big drug companies was also severe. Most people don’t differentiate between generic companies and innovative ones. Martin Shkreli was referred to in the media as a pharmaceutical company drug executive and was dubbed the “Pharma Bro”. Big companies had to come out and publicly dissociate themselves from Shkreli. Merck’s CEO, Ken Frazier spoke for all of Big Pharma when he said: “I think it is really important to our industry to make it clear that he is not us. We are a research-based pharmaceutical industry.” While the Daraprim is the most notorious example, there are others. Drug prices don’t always drop dramatically as happened with Lipitor once its patent expired. Like in any business, the cost of generic drugs is dependent on competition and availability. If a certain generic drug has low margins, there often will be little competition and so prices rise. But now, billionaire entrepreneur Mark Cuban plans to change the generic drug business paradigm with his newly announced venture: “The Mark Cuban Plus Drug Company”. For his first act, Cuban plans to produce albendazole, another antiparasitic drug which retails for $222 per pill, for a cost to patients of $15. Cuban plans full transparency for the cost of developing and manufacturing generic drugs and will charge a flat 15% margin on the 100 drugs he plans to be producing by the end of the year. MORE FOR YOU

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CorePharma Patents

CorePharma has filed 1 patent.

The 3 most popular patent topics include:

  • Cancer treatments
  • Light therapy
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/16/2018

Light therapy, Photochemistry, Tetrapyrroles, Cancer treatments, Molecular biology

Application

Application Date

1/16/2018

Grant Date

Title

Related Topics

Light therapy, Photochemistry, Tetrapyrroles, Cancer treatments, Molecular biology

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.